Clinical Study on the Effect of Zhenyuan Capsule on Cardiopulmonary Function in Patients With SCAD

Inclusion Criteria: * Results of coronary angiography or spiral CT:Patients with coronary artery stenosis ≥ 50%, or with a clear history of myocardial infarction, or stable condition more than one month after ACS treatment (percutaneous coronary intervention therapy, PCI, coronary artery bypass graft, CABG)； * LVEF≥40%； * Angina grade Ⅰ-Ⅱ (CCS grade); * The syndrome differentiation of traditional Chinese medicine is the syndrome of qi deficiency and blood stasis； * 18 years old ≤ age ≤ 75 years old； * In accordance with the risk stratification of cardiac rehabilitation in patients with coronary heart disease, the patients with moderate and low risk can carry out cardiopulmonary rehabilitation by exercise； * Those who sign the informed consent form. Exclusion Criteria: * Patients with acute myocardial infarction or unstable angina pectoris, or within one month after PCI or CABG; * Patients with absolute and relative contraindications in accordance with cardiopulmonary exercise test; * Patients who took Zhenyuan capsule in the past 1 month or participated in other clinical trials in the past 1 month； * Renal insufficiency, serum creatinine \> 2.5mg / dl in male and \> 2.0mg/dl in female； * Patients with obvious liver disease or both ALT and AST were 3 times higher than the normal upper limit； * New York heart function (NYHA) grade IV, or patients with recurrent malignant arrhythmias; * Complicated with chronic obstructive pulmonary disease or even respiratory failure, or complicated with pulmonary infection; * Diabetic patients with random blood glucose ≥ 13.7mmol/L or glycosylated hemoglobin ≥ 9.5%; * Pregnant or preparing pregnant women, lactating women; * Patients with acute cerebrovascular diseases; malignant tumors or patients with life expectancy of less than 1 year; patients with severe hematopoietic diseases; patients with severe mental illness; * For those who are allergic to the known ingredients of the drug.